← Browse by Condition
Medical Condition

mesom

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 1, Phase 2
NCT06051695 Phase 1, Phase 2
Recruiting

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Enrollment
474 pts
Location
United States
Sponsor
A2 Biotherapeutics Inc.
View Trial →